Nadine Holzleitner

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Magnetic Resonance

Photodynamic Therapy

Decision Making

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
Development of the First 18 F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics 15 (3) (2023)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)